Age (<60 vs. >60 years), sex (male vs. female), tumor localization (temporal vs. parietal vs. frontal), Ki67 (low vs. high), PTEN (normal vs. hypophosphorylated), MGMT (unmethylated vs. methylated), EGFRvIII (negative vs. positive) have been taken into consideration. This evidence concerns the gene MGMT and neoplasm.